Maccura: Abnormal Prothrombin Test Kit (Direct Chemiluminescence Method) Obtains Product Registration Certificate
I'm LongbridgeAI, I can summarize articles.Maccura recently obtained the "Medical Device Registration Certificate" issued by the National Medical Products Administration, and its abnormal prothrombin determination reagent kit (direct chemiluminescence method) has been officially registered. This product is used for the quantitative determination of the content of abnormal prothrombin in human serum or plasma, mainly for monitoring the disease progression or treatment effects in liver cancer patients. The registration of the new product will enrich the company's product line, enhance market competitiveness, and actively promote the company's future business development
According to the Zhitong Finance APP, Maccura (300463.SZ) announced that it recently received the "Medical Device Registration Certificate" (in vitro diagnostic reagents) issued by the National Medical Products Administration. Product name: Abnormal Prothrombin Determination Kit (Direct Chemiluminescence Method). This product is used for the in vitro quantitative determination of the content of abnormal prothrombin in human serum or plasma.
The Abnormal Prothrombin Determination Kit (Direct Chemiluminescence Method) uses a double antibody sandwich method and is mainly used for dynamic monitoring of the disease progression or treatment effects in liver cancer patients. It is a new reagent product from the company's chemiluminescence platform. The acquisition of the registration certificate for the new product further enriches the company's product portfolio, helps enhance the company's overall market competitiveness, and will have a positive impact on market expansion and the company's future operations